Gauberti Maxime, Fournier Antoine P, Vivien Denis, Martinez de Lizarrondo Sara
Normandie Univ, UNICAEN, INSERM, INSERM UMR-S U1237, PhIND, Physiopathology and Imaging of Neurological Disorders, Cyceron, Caen, 14000, France.
Department of Diagnostic Imaging and Interventional Radiology, CHU Caen, Caen, France.
Methods Mol Biol. 2018;1718:315-327. doi: 10.1007/978-1-4939-7531-0_19.
Molecular magnetic resonance imaging (mMRI) enables the detection of a protein of interest in vivo, in a noninvasive manner. The general concept of mMRI is to target a contrast agent to a protein of interest, and to perform a contrast-sensitive MRI sequence. Typically, contrast agents are made of a "contrastophore" (the part of the construct responsible for the contrast on the images) and a targeting moiety ("pharmacophore"). Recently, the development of a new family of contrastophore carrying a high payload of iron oxide (micro-sized particles of iron oxide, MPIO) has led to a dramatic increase in the sensitivity of mMRI. Here, we describe the production of targeted MPIO using commercially available reagents and the MRI protocols to allow their detection in vivo.
分子磁共振成像（mMRI）能够以非侵入性方式在体内检测目标蛋白。mMRI的一般概念是将造影剂靶向到目标蛋白上，并执行对比敏感的MRI序列。通常，造影剂由“造影团”（构建体中负责图像上对比的部分）和靶向部分（“药效团”）组成。最近，一种携带高负载量氧化铁的新型造影团（微米级氧化铁颗粒，MPIO）的开发使mMRI的灵敏度大幅提高。在此，我们描述了使用市售试剂生产靶向MPIO以及用于在体内检测它们的MRI方案。
